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Superantigens as immunomodulators: recent structural insights
Anastassios C Papageorgiou and K Ravi Acharya*
Superantigens interact with major histocompatibility
complex (MHC) class II molecules and T-cell receptors
(TcRs) forming a trimolecular complex which is able to
induce proliferation and cytokine production in T cells.
Although superantigens appear to act through a common
mechanism, they vary in many of their specific interactions
and biological properties. X-ray crystallographic studies
and biochemical experiments have now established that
cross-linking of MHC class II molecules and the TcR by
superantigens can occur in a number of different modes.
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Staphylococcus aureus and Streptococcus pyogenes secrete a
number of pyrogenic toxins, known as ‘superantigens’ due
to their potent immunostimulatory properties [1]. Unlike
conventional antigens, superantigens bind to major histo-
compatibility complex (MHC) class II molecules outside
the antigen-binding groove and are presented as unproces-
sed proteins to certain T cells expressing specific T-cell
receptor (TcR) Vβ genes (Figure 1). As a consequence,
superantigens stimulate up to 20% of T cells while only 1
in 105–106 T cells (0.001–0.0001%) are activated upon
normal antigen presentation. Staphylococcal enterotoxins
(SEs) A, B, C1–C3, D and E, toxic shock syndrome toxin-1
(TSST-1) and the streptococcal pyrogenic exotoxins (Spes)
A, B and C are the most well studied superantigens to date.
These toxins are responsible for the production of elevated
amounts of cytokines, such as tumour necrosis factor (TNF)
and interleukin-2 (IL-2), upon T-cell activation [2], and
result in toxic shock, food poisoning and scarlet fever in
man and animals. Other pathogens have also been found
to secrete proteins with superantigenic properties. For
example, Mycoplasma arthritidis (an organism responsible
for inducing chronic arthritis in rodents) produces a 213-
residue soluble protein that acts as a superantigen, al-
though it is only distantly related to microbial superanti-
gens [3]. A number of viral superantigens that share some
common properties with the microbial superantigen family
have also been identified recently [4]. These superanti-
gens have been implicated in several infections caused by
viruses, such as rabies virus, Epstein-Barr virus (EBV) and
human immunodeficiency virus (HIV).
Figure 1
Schematic diagram showing the differences
between the ways in which a conventional
antigen and a superantigen bind to MHC












Superantigens have been studied extensively both at the
structural and functional level. The T-cell proliferation
induced by superantigens has raised the possibility of using
them as fusion products with Fab molecules [5], for tumour
therapy by directing T cells against tumour cells expressing
specific MHC class II antigens. It has also been shown that
superantigens down-regulate the immune response leading
to anergy and/or deletion of T cells [6] and thus they could
also be used to eliminate populations of T cells involved in
autoimmune diseases.
Common architecture 
Microbial superantigens are medium size proteins (MW
22–29 kDa) characterised by high resistance to proteases
and to denaturation by heat. Sequence alignment shows
that SEA, SED and SEE (and probably SEH) form a major
subfamily while SEB and the SECs belong to a separate
subfamily. TSST-1 shows ~28% sequence homology with
other SEs and forms an outlier. Comparison of the struc-
tures of SEB [7], TSST-1 [8,9], SEA [10], SEC2 [11] and
SED [12] shows a conserved two-domain architecture
(N- and C-terminal domains) and the presence of a long,
solvent-accessible α helix spanning the centre of the mol-
ecule (Figure 2). The N-terminal domain is characterised
by the presence of hydrophobic residues in solvent-exposed
regions and has considerable similarity to the oligosaccha-
ride/oligonucleotide-binding fold (OB fold) present in
other proteins of unrelated sequence (e.g. in staphylococcal
nuclease and AB5 toxins). In these other proteins, the OB
fold is involved in DNA binding (staphylococcal nuclease)
or carbohydrate recognition (AB5 toxins); none of these
functions have been attributed to superantigens so far. In
the case of SEB, however, it has been reported that diga-
lactosylceramide can act as a receptor for this toxin [13].
The C-terminal domain comprises a four-stranded β sheet
capped by the central long α helix and has some structural
features of the β-grasp motif present in other proteins, such
as ubiquitin, 2Fe–2S ferredoxin, immunoglobulins and the
Ras-binding domain of the serine/threonine-specific pro-
tein kinase Raf-1.
A common feature of SEA, SEB and SECs, but not of
TSST-1, is the presence of a highly flexible disulphide
loop within the N-terminal domain that has been impli-
cated in the emetic properties of the enterotoxins [14]. It
has been shown that mutation of the cysteine residues to
alanine in SEC1 results in a non-emetic toxin while muta-
tion to serine does not affect the emetic properties imply-
ing that adoption of the appropriate conformation of the
loop may be required for emetic activity. Interestingly,
recent evidence suggests that superantigens are absorbed
as immunologically intact proteins by the epithelium [15].
TSST-1 does not induce emesis and this is consistent
with the potential role of the disulphide loop in emesis
(for SEs). Nevertheless, emesis is a complex event occur-
ring in the gastrointestinal tract and detailed investiga-
tions are required in order to evaluate the structural data.
Moreover, the gastrointestinal problems associated with
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Figure 2
Ribbon diagrams of the crystal structures of
(a) SEA [10], (b) SEB [16] (highly mobile
regions are not shown in this model), 
(c) TSST-1 [19] and (d) SEC2 [11]. The
disulphide bridge is shown in ball-and-stick
representation. The large purple sphere
represents the zinc ion. The TcR- and MHC-
binding sites of SEB and TSST-1 are shown
(SEB, SEC2 and SEA share similar binding
sites). The zinc ion mediated MHC class II
association is discussed in the text.
superantigens could be due to leukotriene or histamine
release rather than T-cell activation. 
The MHC class II-binding site
Details about the interactions of superantigens with MHC
class II molecules have been derived from the structures
of SEB and TSST-1 in complex with an MHC class II
molecule HLA-DR1 [16,17]. In both complexes, a similar
binding mode was found involving the α chain of DR1.
However, an additional contact region was apparent in the
TSST-1–DR1 complex involving the β chain of the DR1
molecule, the peptide antigen and the TSST-1 β4–β5
loop (Figure 3) [17].
Residues 43–47 from the N-terminal domain of SEB form
the first contact region (mainly hydrophobic) at the SEB–
DR1 interface [16]. In particular, Phe44, Leu45 and Phe47
point into a hydrophobic pocket in the DR1 α chain
created by Tyr13, Met36, Ala37, Leu60, Ile63 and Ala64.
Substitution of either Phe44 or Leu45 reduces the binding
affinity of SEB for MHC class II molecules [18]. In TSST-
1, the corresponding region is located around Leu30. In
the free TSST-1 structure [19], Leu30 is solvent-exposed
but upon complex formation its sidechain moves towards
the same hydrophobic cavity of DR1 as observed in the
SEB–DR1 complex. Residues Asp27 and Gln43, of TSST-
1 and SEB respectively, both form hydrogen bonds with
Gln18 and Lys67 of the DR1 α chain. The second contact
region (mainly polar) is dominated by interactions medi-
ated by residue Lys39 of DR1. In the TSST-1–DR1 com-
plex, Lys39 forms hydrogen bonds with Pro50 and Ser53
but in the SEB–DR1 complex it makes a salt bridge with
SEB Glu67. Furthermore, Lys39 is hydrogen bonded to
two other SEB residues, Tyr89 and Tyr115. It is clear that
Lys39 of DR1 is an important residue and when mutated
to alanine, binding of TSST-1 or SEB to the DR1 mol-
ecule is disrupted [16]. A third contact region was identi-
fied in the TSST-1–DR1 complex involving residues
73–80 (part of a mobile loop) of TSST-1. This loop under-
goes a significant movement of up to 4 Å [19] as a result of
the complex formation in order to optimise TSST-1 con-
tacts with the DR1 β chain (residues 55–63) and the
peptide antigen.
Despite the similarity and the apparent overlap of their
respective MHC-binding sites, SEB and TSST-1 do not
compete with each other for MHC class II molecules. It
was proposed that cellular factors (e.g. peptides) may affect
the presentation of TSST-1 to MHC class II molecules
[20,21]. Hence, only a portion of MHC class II molecules
carrying the appropriate peptides could bind TSST-1 on
the cell surface and present it to the T-cell receptor.
Similar suggestions have been put forward for SEB. 
SEA, SEC2 and SED: the role of zinc
Earlier biochemical studies suggested the presence of an
intrinsic zinc ion in SEA and SEE and indeed mutational
analysis identified His187, His225 and Asp227 in these
toxins as the zinc ligands [22]. The structure determina-
tion of SEA confirmed the presence of a zinc-binding site
within this toxin [10,23] in the lower part of the molecule
in the C-terminal domain, far from the equivalent MHC-
binding site of SEB. It was suggested that the zinc ion
could act as a bridge cross-linking the superantigen with
the MHC class II molecule. In this case, an appropriate
fourth zinc ligand should be provided by the MHC class
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Figure 3
Ribbon diagrams of the structures of two
superantigen–DR1 complexes: (a) SEB–DR1
[16] and (b) TSST-1–DR1 [17]. The peptide
antigen is coloured in yellow; α helices are in
red and β sheets in green.
II molecule for stabilisation of the complex. A potential
ligand is His81 from the β chain of the DR1 molecule, as
mutation of this residue disrupts SEA but not SEB or
TSST-1 binding [24]. Nevertheless, SEA competes with
SEB for MHC class II molecules and based on biochemi-
cal and structural evidence it is now clear that this toxin
possesses two binding sites for MHC class II molecules:
a high affinity site involving zinc (Kd = 100 nM) and a
low affinity SEB-like site (Kd = 10 µM). However, SEA
exhibits a Kd of 13 nM for MHC class II molecules if the
two binding sites co-exist [25]. It has recently been
shown that cells treated with either Phe47→Ala or
Asp227→Ala SEA mutants (i.e. with inactivated low-
affinity and high-affinity sites, respectively) are unable to
express cytokines [26]. Therefore, it may be possible for
the two MHC-binding sites to cooperate in the formation
of a bivalent complex. This has gained further support
from recent experimental data which showed the forma-
tion of (SEA)2–DR1 trimers in solution [27]. Indeed, a
simple molecular modelling exercise can demonstrate
the plausibility of the existence of such trimers
(Figure 4). An interesting feature of this model is that the
peptide antigen site seems to be partially blocked by the
second SEA molecule that binds to DR1 through the
zinc ion. In agreement with this observation, it has been
shown that the N-terminal region of the peptide affects
SEA binding [28]. However, the exact role of the peptide
antigen in modulating SEA activity/binding has yet to be
established.
A zinc-binding site has also been found in SEC2 [11],
formed by His118, His122, Asp83 from one molecule and
Asp9 from a neighbouring SEC2 molecule in the crystal
lattice. Even though the SEC2 zinc-binding site is dis-
tinct from that of SEA, the dissociation constant for the
zinc ion in SEC2 was estimated to be < 1 µM and is com-
parable to that observed for SEA. Using SEC1 deletion
mutants, Hoffmann et al. [29] identified a region in 
SEC1 coincident with the SEC2 zinc-binding site which
could bind MHC class II molecules. Furthermore,
binding studies in SEC2 and SEE suggested a model in
which each of these two toxins could cross-link two adja-
cent MHC class II molecules [30]. Therefore, the possi-
bility that SEC2 may have a second MHC class II-
binding site cannot be ruled out.
Another variation in the superantigen binding to MHC
class II molecules was recently revealed in the crystal
structure of SED [12]. In this superantigen, the zinc ion
(ligands — Asp 182, His 220 and Asp 222) induces homod-
imerisation of the enterotoxin with each monomer able to
bind an MHC class II molecule in an SEB-like mode.
Under certain conditions, however, SED may act as a
monomer to bind MHC class II molecules in an SEA-like
mode. Thus, the available data suggest that each super-
antigen has developed distinct MHC-recognition modes. 
The TcR-binding site
Mutagenesis and structural data have shown that the TcR-
binding site in SEB involves a shallow cavity between the
two domains of the molecule, created by residues 22–33
(mostly α2 helix), 55–61 (β2–β3 loop), 87–92 (β4 strand
and β4–β5 loop), 112 (β5 strand) and 210–214 (α5 helix)
[7]. Analogous sites have been proposed for SEC2, SEC1
and SEA. Direct structural insights into the interactions
of superantigens with the TcR were recently provided by
the crystal structures of SEC2 and SEC3 in complex with
a TcR Vβ chain at 3.5 Å [31], confirming previous experi-
mental data. From this study, residues from the comple-
mentarity determining regions 1 and 2 (CDR1 and CDR2)
and hypervariable region 4 (HV4) of the Vβ chain can be
inferred to be involved in superantigen binding. The
binding is mainly mediated by interactions between side-
chain atoms of SEC2/SEC3 with backbone atoms of the
TcR Vβ chain.
Close examination of the TcR-binding site in SEA, SEB
and SEC2 reveals both similarities and differences be-
tween the three superantigens. An invariant asparagine
residue (Asn23 in SEB/SECs; Asn25 in SEA) is thought to
be crucial for direct interactions with the TcR and its
mutation abolishes T-cell activation in SEB [18]. This
residue is solvent-exposed in SEA, SEB and SEC2 and is
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Figure 4
A model of the bivalent SEA binding to an MHC class II molecule. The
two SEA molecules are coloured in red and cyan. The α and β
domains of the DR1 are coloured in green and yellow, respectively.
SEA zinc ligands and His81 from the β1 domain of the MHC class II
molecule are shown in ball-and-stick representation. The zinc ion is
shown as a grey sphere.
probably involved in a similar type of interaction with the
TcR in all the enterotoxins (in the complex, its sidechain
forms two hydrogen bonds with Thr55 from the TcR).
However, variances in the TcR specificity/binding affinity
could be explained by differences in other residues. One of
these residues, Tyr26 of SEC2, is a key residue conferring
specificity between SEC1 and SEC2 [32] and contacts
Gly53 from the TcR Vβ chain [31]; this residue is not con-
served in either SEB or SEA (valine and glutamine, respec-
tively). Another SEC2 residue (Val91) implicated in TcR
binding is not conserved in either SEA or SEB (Tyr94 and
Tyr91, respectively) [33]. It is thought that replacement of
Val91 by a tyrosine residue may be responsible for the
reduced affinity of SEB for the Vβ8.2 chain [31].
It has been proposed that Ser206, Asn207 and Thr21 are
the specificity defining residues in SEA [33]. Hudson et
al. [34] have shown that an exchange of residues 206 and
207 in SEA to the homologous residues in SEE convert
the SEA profile of responding TcR Vβ families in human
T cells to that of SEE. In SEA, Ser206 is situated at the
bottom of the TcR-binding cavity, while Asn207 points
away from the cavity. Serine 206 and Asn207 correspond
to Gln210 and Ser211, respectively, in SEC2 as well as in
SEB. These residues are located in a region with large
deviations of the Cα chains between SEA and SEC2/
SEB. In general, the flexibility observed in some regions
of the TcR-binding site might be an important compo-
nent in superantigen recognition. Regions involved in
interactions with the TcR Vβ chain includes two highly
flexible external loops in the uncomplexed SEC2 struc-
ture: β2–β3 and α5–β9. The latter loop shows a large
deviation (some 5 Å) when compared with the struc-
turally equivalent loop in SEA.
The TcR-binding site of TSST-1 is distinct from that of
the SEs and is believed to be located in the C-terminal
domain, on the long α2 helix and between the β7–β8 and
α2–β9 loops and part of the α1 helix. Mutagenesis studies
have shown that changes in the region encompassing
residues 115–144 (particularly in residues Tyr115,
Glu132, His135, Ile140, His141 and Tyr144) result in
partial or complete loss of mitogenicity [9]. Almost all of
these residues were found to be located in an elongated
cleft of about 12 Å in width. Glu132 is situated in the
middle of the cleft with its sidechain solvent-exposed.
The negative charge of Glu132 was found to be crucial for
TcR binding as mutation of this residue to lysine resulted
in a 1000-fold less mitogenic form of TSST-1 [35]. Muta-
tion of Glu132 and His135 of the TSST-1 α2 helix abol-
ished superantigenicity but the toxin was still recognised
by a specific antibody, indicating no significant changes
in the structure [9]. The structure determination of the
His135→Ala TSST-1 mutant revealed no major changes
in the structure although a perturbation of the neighbour-
ing α1 helix was observed [36]. 
Looking at the future
A combination of mutagenesis and structural studies has
now established that superantigens show variability in their
interactions with MHC class II molecules. More specifi-
cally, the presence of a zinc-binding site, in SEA, SEC2
and SED, and the effect of specific peptides in TSST-1
presentation, suggest alternative MHC-binding modes not
previously seen in TSST-1–DR1 or SEB–DR1 complexes.
It is still not known how these different MHC-binding
modes affect the formation of the TcR–superantigen–
MHC ternary complex or what the functional benefit of
this variability would be. It is possible that multivalent
binding sites for MHC class II molecules could lead to the
engagement of more than one TcR molecule, thus enhanc-
ing the superantigen potency. Although superantigens bind
to the TcR Vβ chain, the Vα chain may also play a role in
superantigen presentation. A hypothetical model (Figure 5)
can show no direct contacts between the superantigen and
the TcR Vα chain. Instead, interactions between the DR1
β chain and the TcR Vα chain may contribute to the stabil-
ity of the ternary complex. As TSST-1 binds to the TcR
Vβ in a different manner to SEs, the role of Vα may be
altered in this case and the TcR may not be able to contact
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Figure 5
Worm representation of a hypothetical model of the
MHC–superantigen–TcR ternary complex based on the crystal
structures of SEB–DR1 [16], TcR Vβ–SEC3 [31] and the TcR VαVβ
heterodimer [37].
DR1 but only TSST-1. The role of other molecules in the
stabilisation of the TcR Vβ–superantigen complex has also
been suggested, in particular for the SECs and SEE which
are able to activate T cells even in the absence of MHC
class II molecules. Based on sequence alignment data
other superantigens, for example Streptococcus pyogenes exo-
toxin A, also appear to possess a zinc-binding site. How-
ever, the exact role of this ion in toxin recognition must
wait for the availability of direct structural data. 
Structural and biochemical data have shed light on how
the superantigens work. Although many questions remain
unanswered as yet, it is certain that new exciting develop-
ments will emerge in the coming years regarding molecu-
lar recognition by superantigens. Undoubtedly, the study
of this family of molecules will help in understanding the
immune system and should provide leads towards the
development of new therapeutic agents.
Note added in proof
After this minireview was submitted, the crystal structure of Streptococcus
pyogenes enterotoxin C at 2.4 Å resolution was reported (Roussell, A., Ander-
son, B.F., Baker, H.M., Fraser, J.D. & Baker E.N. (1997). Crystal structure of
the streptococcal superantigen SPE-C: dimerization and zinc binding suggest
a novel mode of interaction with MHC class II molecules. Nat. Struct. Biol. 4,
635–643). Two zinc-binding sites were identified in this enterotoxin. Based on
crystallographic and biochemical data, the authors propose a new MHC-
binding mode. The normal SEB-like MHC-binding site in this toxin appears to
be absent due to the presence of a zinc ion at the N-terminal domain that
induces homodimerisation of the toxin. Instead, the MHC binding appears to
involve the second zinc-binding site (analogous to the zinc-binding site of
SEA). The overall fold is considerably similar to staphylococcal superantigens.
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